Daily Anesthesiology Research Analysis
Analyzed 87 papers and selected 3 impactful papers.
Summary
Three impactful studies span mechanistic sepsis biology, precision antibiotic dosing on ECMO, and evidence synthesis for buffer therapy in acute metabolic acidosis. A Science Advances paper uncovers Drp1-driven tunneling nanotubes as conduits for mitochondrial transfer in septic hearts, while a J Antimicrobial Chemotherapy population-PK study recommends meropenem 1 g q8h continuous infusion during ECMO. A systematic review in Acta Anaesthesiologica Scandinavica finds buffering likely reduces RRT use (not mortality) in ICU AKI.
Research Themes
- Sepsis nanobiology and mitochondrial communication
- Precision dosing and PK/PD optimization during ECMO
- Buffer therapy in acute metabolic acidosis (critical care)
Selected Articles
1. Cytoskeletal remodeling promotes tunneling nanotube formation and drives cardiac resident cell mitochondrial transfer in sepsis.
Using a CLP sepsis model and single-cell RNA-seq, the authors show that Drp1-driven cytoskeletal remodeling orchestrates tunneling nanotube biogenesis in cardiac cells, enabling long-range mitochondrial trafficking. Drp1’s interaction with Filamin and Kinesin regulates TNT formation/extension, and cardiac-specific Drp1 knockout disrupts mitochondrial exchange, halting metabolic deterioration and reversing cellular reprogramming.
Impact: This study uncovers a nanoscale organelle-communication mechanism that links cytoskeletal remodeling to metabolic failure in septic cardiomyopathy and identifies Drp1 as a tractable target.
Clinical Implications: While preclinical, targeting Drp1/TNT-mediated mitochondrial exchange could represent a novel strategy to prevent or reverse septic cardiomyopathy; translation will require validation in human tissues and pharmacologic modulation studies.
Key Findings
- Sepsis reprogrammed cardiac endothelial cells, fibroblasts, and macrophages into metabolically impaired subpopulations with dysfunctional mitochondrial respiration.
- Drp1-driven cytoskeletal remodeling, via interactions with Filamin and Kinesin, orchestrated TNT biogenesis and extension for organelle trafficking.
- Cardiac-specific Drp1 knockout disrupted TNT-mediated mitochondrial exchange, halting metabolic deterioration and reversing cellular reprogramming.
Methodological Strengths
- Integrated multi-modal approach combining in vivo CLP sepsis, single-cell RNA-seq, protein interaction analyses, and imaging.
- Genetic validation using cardiac-specific Drp1 knockout to establish causality.
Limitations
- Preclinical mouse model without human tissue validation limits direct translational generalizability.
- Lack of survival or organ-level functional outcomes beyond cellular/metabolic endpoints.
Future Directions: Validate TNT-mediated mitochondrial transfer and Drp1 dependency in human septic myocardium; test pharmacologic Drp1 modulators; map TNT networks across cell types and disease stages; quantify organ-level functional rescue.
Sepsis-induced cardiac dysfunction arises from complex intercellular communication networks that extend beyond direct cardiomyocyte damage, yet the nanoscale mechanisms governing these interactions remain poorly understood. Here, we identify tunneling nanotubes (TNTs) as dynamic biological nanostructures facilitating intercellular mitochondrial transfer, revealing their critical role in septic cardiac remodeling. Using a murine cecal ligation and puncture (CLP) model and single-cell RNA sequencing, we demonstrate
2. Population pharmacokinetics of meropenem in critically ill adult patients receiving extracorporeal membrane oxygenation-an ASAP ECMO study.
In 18 ECMO patients (150 samples), meropenem PK followed a two-compartment model; ECMO flow increased central volume, while creatinine clearance and RRT increased clearance. Monte Carlo simulations support 1 g q8h continuous infusion to achieve Cmin ≥2 mg/L with low toxicity risk across scenarios, including with RRT, and robustness for Cmin ≥8 mg/L in most cases.
Impact: Provides actionable, model-informed dosing guidance for meropenem during ECMO, a setting with altered PK where under- or overdosing risks are high.
Clinical Implications: Adopt continuous infusion meropenem 1 g q8h during ECMO (with or without RRT) as a default starting regimen, with adjustment for renal function and consideration of TDM to individualize targets.
Key Findings
- Two-compartment PK model best described meropenem during ECMO; ECMO flow increased central volume of distribution.
- Estimated creatinine clearance and concomitant RRT significantly influenced drug clearance.
- Continuous infusion 1 g q8h achieved efficacy targets (Cmin ≥2 mg/L; often ≥8 mg/L) with low probability of toxicity (>45 mg/L), including in RRT.
Methodological Strengths
- Validated bioanalytical assay with serial rich sampling (150 time points).
- Population PK modeling with Monte Carlo simulations to translate findings into dosing recommendations.
Limitations
- Small sample size (n=18) and single-interval sampling limit external validity.
- No assessment of clinical outcomes (e.g., microbiologic cure, mortality) tied to dosing strategies.
Future Directions: Prospective trials assessing outcome-linked PK/PD targets with TDM-guided dosing during ECMO; external validation across ECMO circuits and flow ranges; evaluation of higher MIC pathogens.
OBJECTIVES: To describe meropenem population pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation (ECMO) with or without renal replacement therapy (RRT), and to identify dosing regimens likely to achieve safe and effective exposures. METHODS: Serial blood samples were collected over a single dosing interval during ECMO. Total plasma concentrations were measured by a validated assay. Population pharmacokinetic modelling and Monte Carlo dosing simulations were performed u
3. Bicarbonate and Other Buffer Therapies in Acute Metabolic Acidosis: A Systematic Review and Meta-Analysis.
Across 14 trials (n concentrated in ICU, OHCA, and intraoperative settings), buffering—mostly bicarbonate—likely reduces RRT use and bloodstream infections in ICU patients with AKI, but probably does not improve survival. In out-of-hospital cardiac arrest, no survival effect was detected. Risk of bias was generally moderate; certainty ranged from very low/low (mortality) to moderate (RRT, infections).
Impact: Provides an up-to-date, methodologically rigorous synthesis clarifying where buffer therapy may help (RRT reduction) and where it does not (survival), informing protocolized critical care practice.
Clinical Implications: Consider selective buffer therapy (e.g., bicarbonate) in ICU AKI with severe metabolic acidosis to reduce RRT initiation and bloodstream infections; do not expect survival benefit and avoid indiscriminate use, especially in OHCA.
Key Findings
- Fourteen RCTs were synthesized, largely in ICU AKI, out-of-hospital cardiac arrest, and intraoperative acidosis cohorts; bicarbonate was the predominant intervention.
- In ICU patients with AKI, buffer therapy likely reduces RRT use and bloodstream infections (moderate certainty).
- No meaningful effect on survival outcomes was found in ICU AKI (low certainty) or OHCA (very low to low certainty).
Methodological Strengths
- PRISMA-conformant systematic review with RoB2 risk-of-bias assessment and GRADE certainty ratings.
- Focused on randomized clinical trials with clear subgroup contexts (ICU AKI, OHCA, intraoperative acidosis).
Limitations
- Clinical and methodological heterogeneity across trials (patient phenotypes, dosing, timing) limits pooled inference.
- Moderate risk of bias in many trials and limited power for mortality outcomes.
Future Directions: Large pragmatic RCTs targeting biochemical phenotypes (pH, bicarbonate deficit, lactate) with patient-centered outcomes; evaluate timing/dose strategies and adverse effects; cost-effectiveness analyses.
BACKGROUND: The aim of this study was to perform a systematic review and meta-analysis on the effect of buffering therapies on clinical outcomes in adult patients with acute metabolic acidosis. METHODS: Searches were conducted in Embase, Cochrane, and PubMed for randomised clinical trials comparing a buffering therapy to either placebo, no buffering therapy, or another buffering therapy in adult patients with acute metabolic acidosis. Two assessors independently reviewed trials for relevance, extract